Pilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain

Published Date: 10 Mar 2025

Based on the results of PROGRESS and the previous RELIEF-DPN-1 study, the 10 mg dose of pilavapadin was selected to move forward in clinical development for diabetic peripheral neuropathic pain.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot